Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT ID: NCT07668388
Registry status: Recruiting
Study type: Not specified in the registry data
Phase: Phase 2
Sponsor: Novo Nordisk A/S

Overview

ClinicalTrials.gov lists this study as Recruiting.

Enrollment: 300 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages: Not specified in the registry data
Sex: Not specified in the registry data
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening. * Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor. * HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol/mol)) (both inclusive) as assessed by central laboratory at screening. * Body mass index between 25.0 kg/m\^2 and 50.0 kg/m\^2 (both inclusive) at screening. Exclusion Criteria: * Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.

Study locations

70 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Australia, Germany, Hungary, Poland, Romania, Slovakia, South Korea, Spain, United States

New South Wales, Australia: 4
South Australia, Australia: 1
Victoria, Australia: 1
Bavaria, Germany: 1
Csongrád-Csanád, Hungary: 1
Lublin Voivodeship, Poland: 1
Podlaskie Voivodeship, Poland: 1
Dolj, Romania: 1
Barcelona, Spain: 1
Alabama, United States: 1
California, United States: 4
Florida, United States: 3
Indiana, United States: 1
Kansas, United States: 1
Maryland, United States: 1
North Carolina, United States: 2
North Dakota, United States: 1
Pennsylvania, United States: 1
South Carolina, United States: 1
Tennessee, United States: 1
Texas, United States: 6
Utah, United States: 1
Washington, United States: 1

Sample of listed locations

Castle Hill Medical Centre — Castle Hill, New South Wales, 2154, Australia — Site recruitment status not specified in the registry data
Novatrials — Charlestown, New South Wales, 2290, Australia — Site recruitment status not specified in the registry data
Hunter Medical Research Institute - Endocrinology and Diabetes — New Lambton Heights, New South Wales, 2305, Australia — Site recruitment status not specified in the registry data
Roger Chih Yu Chen — Sydney, New South Wales, 2148, Australia — Site recruitment status not specified in the registry data
Royal Adelaide Hospital - Cardiology Department — Adelaide, South Australia, 5000, Australia — Site recruitment status not specified in the registry data
Baker Heart and Diabetes Institute — Melbourne, Victoria, 3004, Australia — Site recruitment status not specified in the registry data
Versdias - Diabetologikum Amberg — Amberg, Bavaria, 92224, Germany — Site recruitment status not specified in the registry data
Herz- und Diabeteszentrum NRW - Bad Oeynhausen — Bad Oeynhausen, 32545, Germany — Site recruitment status not specified in the registry data
Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR — Berlin, 13597, Germany — Site recruitment status not specified in the registry data
DSP Bochum, Diabetes- und Stoffwechselpraxis — Bochum, 44869, Germany — Site recruitment status not specified in the registry data
Studiengesellschaft Dres. Könemann/Steinmann GbR — Bünde, 32257, Germany — Site recruitment status not specified in the registry data
InnoDiab Forschung GmbH — Essen, 45136, Germany — Site recruitment status not specified in the registry data
Mesut Durmaz, Hof — Hof, 95030, Germany — Site recruitment status not specified in the registry data
CRS Clinical Research Services Mannheim GmbH (hVIVO Mannheim) — Mannheim, 68167, Germany — Site recruitment status not specified in the registry data
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ — Szeged, Csongrád-Csanád, 6725, Hungary — Site recruitment status not specified in the registry data
PVN Kutató Kft. — Budapest, 1102, Hungary — Site recruitment status not specified in the registry data
Semmelweis Egyetem — Budapest, 1083, Hungary — Site recruitment status not specified in the registry data
Szent Margit Rendelőintézet Nonprofit Kft. — Budapest, 1032, Hungary — Site recruitment status not specified in the registry data
Pécsi Tudományegyetem ÁOK — Pécs, 7624, Hungary — Site recruitment status not specified in the registry data
1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ — Lublin, Lublin Voivodeship, 20-049, Poland — Site recruitment status not specified in the registry data
NZOZ Vita-Diabetica Malgorzata Buraczyk — Bialystok, Podlaskie Voivodeship, 15-879, Poland — Site recruitment status not specified in the registry data
Uniwersytecki Szpital Kliniczny w Bialymstoku — Bialystok, 15-276, Poland — Site recruitment status not specified in the registry data
Specjalistyczna Praktyka Lekarska Diabetologia, Leczenie Cukrzycy i Otyłości lek. Monika Piwowar — Kielce, 25-355, Poland — Site recruitment status not specified in the registry data
Clinical Best Solutions Sp. z o.o., Sp. k — Lublin, 20-011, Poland — Site recruitment status not specified in the registry data
Formed 2 Sp. z o.o. — Oświęcim, 32-600, Poland — Site recruitment status not specified in the registry data

Study details

Start date: June 22, 2026
Primary completion date: October 4, 2027
First posted: June 25, 2026

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07668388
Registry last updated: September 11, 2026
QualifiedStudies registry data refreshed: September 21, 2026

View NCT07668388 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Diabetes (Type II) studies | Clinical trial FAQ